A reassessment of the pseudoneglect effect: Attention allocation systems are selectively engaged by semantic and spatial processing.

Healthy individuals display systematic inaccuracies when allocating attention to perceptual space. Under many conditions, optimized spatial attention processing of the right hemisphere's frontoparietal attention network directs more attention to the left side of perceptual space than the right. This is the pseudoneglect effect. We present evidence reshaping our fundamental understanding of this neural mechanism. We describe a previously unrecognized, but reliable, attention bias to the right side of perceptual space that is associated with semantic object processing. Using an object bisection task, we revealed a significant rightward bias distinct from the leftward bias elicited by the traditional line bisection task. In Experiment 2, object-like shapes that were not easily recognizable exhibited an attention bias between that of horizontal lines and objects. Our results support our proposal that the rightward attention bias is a product of semantic processing and its lateralization in the left hemisphere. In Experiment 3, our novel object-based adaptation of the landmark task further supported this proposition and revealed temporal dynamics of the effect. This research provides novel and crucial insight into the systems supporting intricate and complex attention allocation and provides impetus for a shift toward studying attention in ways that increasingly reflect our complex environments. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids.

Cancer Biomarkers have the capability to improve patient outcomes. They have potential applications in diagnosis, prognosis, monitoring of disease progression and measuring response to treatment. This type of information is particularly useful in the individualisation of treatment regimens. Biomarkers may take many forms but considerable effort has been made to identify and quantify proteins in biological fluids. However, a major challenge in measuring protein in biological fluids, such as plasma, is the sensitivity of the assay and the complex matrix of proteins present. Furthermore, determining the effect of proteases in disease requires measurement of their activity in biological fluids as quantification of the protein itself may not provide sufficient information. To date little progress has been made towards monitoring activity of proteases in plasma. The protease asparaginyl endopeptidase has been implicated in diseases such as breast cancer, leukaemia and dementia. Here we describe a new approach to sensitively and in a targeted fashion quantify asparaginyl endopeptidase activity in plasma using a synthetic substrate peptide protected from nonspecific hydrolysis using D-amino acids within the structure. Our selected reaction monitoring approach enabled asparaginyl endopeptidase activity to be measured in human plasma with both a high dynamic range and sensitivity. This manuscript describes a paradigm for future development of assays to measure protease activities in biological fluids as biomarkers of disease.